全文获取类型
收费全文 | 531篇 |
免费 | 43篇 |
国内免费 | 3篇 |
专业分类
儿科学 | 22篇 |
妇产科学 | 27篇 |
基础医学 | 76篇 |
口腔科学 | 5篇 |
临床医学 | 33篇 |
内科学 | 131篇 |
皮肤病学 | 6篇 |
神经病学 | 77篇 |
特种医学 | 7篇 |
外科学 | 24篇 |
综合类 | 4篇 |
预防医学 | 27篇 |
眼科学 | 31篇 |
药学 | 55篇 |
肿瘤学 | 52篇 |
出版年
2024年 | 2篇 |
2023年 | 8篇 |
2022年 | 19篇 |
2021年 | 29篇 |
2020年 | 27篇 |
2019年 | 28篇 |
2018年 | 33篇 |
2017年 | 24篇 |
2016年 | 24篇 |
2015年 | 17篇 |
2014年 | 29篇 |
2013年 | 27篇 |
2012年 | 46篇 |
2011年 | 40篇 |
2010年 | 19篇 |
2009年 | 21篇 |
2008年 | 30篇 |
2007年 | 33篇 |
2006年 | 27篇 |
2005年 | 22篇 |
2004年 | 18篇 |
2003年 | 19篇 |
2002年 | 9篇 |
2001年 | 6篇 |
2000年 | 6篇 |
1999年 | 3篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1990年 | 4篇 |
1987年 | 2篇 |
1983年 | 1篇 |
1979年 | 1篇 |
排序方式: 共有577条查询结果,搜索用时 875 毫秒
571.
Sociodemographic risk,parenting, and inhibitory control in early childhood: the role of respiratory sinus arrhythmia
下载免费PDF全文
![点击此处可从《Journal of child psychology and psychiatry, and allied disciplines》网站下载免费的PDF全文](/ch/ext_images/free.gif)
572.
Increased prevalence of disordered eating in the dual diagnosis of type 1 diabetes mellitus and celiac disease
下载免费PDF全文
![点击此处可从《Pediatric diabetes》网站下载免费的PDF全文](/ch/ext_images/free.gif)
573.
Kirschner Peretz Noa Segal Sofia Shapira Rotem Shemla Ori Lukyanenko Yevgeniya Brosh Inbar Lakatta Edward G. Tsutsui Kenta Yaniv Yael 《Age (Dordrecht, Netherlands)》2023,45(1):209-219
GeroScience - The prevalence of atria-related diseases increases exponentially with age and is associated with ATP supply-to-demand imbalances. Because evidence suggests that cAMP regulates ATP... 相似文献
574.
Masahito Katsuki MD Yasuhiko Matsumori MD PhD Junko Kawahara Chinami Yamagishi Akihito Koh MD Shin Kawamura MD Kenta Kashiwagi MD Tomohiro Kito MD PhD Masato Oguri MD PhD Shoji Mizuno MD PhD Kentaro Nakamura MD PhD Katsushi Hayakawa Osamu Ohta Noa Kubota Hina Nakamura Jun Aoyama Isamu Yamazaki Satoshi Mizusawa Yasuhide Ueki Maiko Nanri Yuki Miyakoshi Shuto Gobo Akio Entani MD PhD Toshiko Yamamoto Miyako Otake Takashi Ikeda Mitsuhiro Matsuo MD PhD Fuminori Yamagishi MD PhD 《Headache》2023,63(3):429-440
575.
576.
Tamir Shragai Hila Magen Noa Lavi Moshe Gatt Svetlana Trestman Miri Zektser Chezi Ganzel Osnat Jarchowsky Tamar Berger Tamar Tadmor Merav Leiba Katrin Hertzog-Tzarfaty Netanel Horowitz Michael Shapira David Varssano Yoav Berger Shahar Frenkel Mark Krauthammer Irit Avivi Efrat Luttwak Yael C. Cohen for the Israeli myeloma study group 《British journal of haematology》2023,200(1):45-53
Belantamab mafodotin, an immuno-conjugate targeting B-cell maturation antigen, showed single-agent activity in phase 1 and 2 studies, and was recently approved for heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. Real-world data and long-term follow-up are scarce. We conducted a multisite retrospective study aimed to assess safety and efficacy of belantamab mafodotin monotherapy administered via the GSK expanded access compassionate care programme. One-hundred and six RRMM patients were treated with belantamab mafodotin between July 2019 and March 2021. The median age was 69.4 years. Patients were heavily pretreated with a median of six (range 2–11) prior therapy lines. Major adverse effects included ocular toxicity (keratopathy 68.4%, grade ≥3: 40.5%; blurred vision 36.8%, grade ≥3: 6.3%), thrombocytopenia (27.4%, grade ≥3: 17.9%) and infections (11.3%, grade ≥3: 7.5%). Median follow-up time was 11.9 [95% confidence interval (CI) 10.0–13.8] months. Overall response rate was 45.5%. Median progression-free survival was 4.7 (95% CI 3.5–5.9) months in the entire cohort and 8.8 (95% CI 6.6–10.9) months among responders. Median overall survival was 14.5 (95% CI 9.5–19.6) months, and not reached for responders. To conclude, in a real-world setting, belantamab mafodotin monotherapy showed efficacy comparable with the prospective clinical trials, with a tolerable toxicity profile. 相似文献
577.